6CM
AVEO

683 Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

683 Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-50,000
Closed -$1.13M – 188
2018
Q2 		$1.13M Buy
+50,000
New +$1.19M 0.08% 96

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

683 Capital Management's AVEO Position: Q3 2020 in Review

683 Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2020, closing a stake of 335,880 shares — an estimated $1.73M sold.

683 Capital Management first reported a position in AVEO in Q4 2016 and held it in 11 quarters. The position peaked at $9.18M in Q3 2017. 63 funds tracked by Wall St. Rank hold AVEO as of Q3 2020.

  • 683 Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • 683 Capital Management sold 335,880 AVEO Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.73M.
  • 683 Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2016 and held it in 11 quarters.
  • 683 Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $9.18M in Q3 2017.
  • 63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2020.

Based on 683 Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.